Therapeutic strategy of relative hypoparathyroidism in hemodialysis patients using sevelamer hydrochloride, with special reference to vitamin D administration

Therapeutic strategy of relative hypoparathyroidism in hemodialysis patients using sevelamer hydrochloride, with special reference to vitamin D administration - The effect of sevelamer hydrochloride on relative hypoparathyroidism in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000475

Enrollment

Registered

2006-09-01

Start date

2006-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relative hypoparathyoidism in maintenance hemodialysis patients

Interventions

Replacement of calcium carbonate with sevelamer hydrochloride as phosphate binder

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Maintenance hemodialysis patients with intact-PTH of 150 pg/ml or less, and receiving calcium carbonate alone as phosphate binder

Exclusion criteria

Exclusion criteria: Hospitalized or medically unstable patients

Design outcomes

Primary

Measure	Time frame
Changes in serum levels of calcium, phosphate, parathyroid hormone, and bone metabolism markers	—

Countries

Japan

Contacts

Public ContactToru Inoue

Osaka Medical College Blood Purification Center

t-inoue@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026